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INTRODUCTION 
Liver Imaging Reporting and Data System (LI-RADS) is a system 
for interpreting and reporting of computed tomography (CT) and 
magnetic resonance imaging (MRI) examinations of the liver in 
patients at risk for hepatocellular carcinoma (HCC). 
As imaging plays an important role in the management of pa-
tients with or at high risk for HCC, several worldwide scientific or-
ganizations and societies have issued guidelines for appropriate 
utilization of imaging for HCC diagnosis.1-6 However, the current 
imaging-based diagnostic criteria have several limitations, includ-
ing the lack of established consensus regarding the exact defini-
tions of imaging features, binary categorization (either definite or 
not definite HCC), and failure to address non-HCC malignancies 
and vascular invasion. To address the limitations of prior systems, 
American College of Radiology (ACR) supported the development 
of LI-RADS with a goal of standardizing the interpreting, report-
ing, and data collection of HCC imaging, and its first version was 
officially launched in 2011.
Prior imaging-based diagnostic systems have not precisely de-
fined or illustrated the imaging features used to assess hepatic le-
sions, which leads to ambiguity in implementation and limits re-
producibility both in clinical care and in research.7 For example, 
should arterial phase hyperenhancement rely on higher attenua-
tion/signal in the arterial phase or calculated change in intensity/
signal between pre- and post-contrast enhancement? In contrast, 
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LI-RADS provides the detailed descriptions and supporting illus-
trations of all imaging features defined.8
Prior systems generally categorize hepatic lesions as positive, 
negative, or indeterminate for HCC; for the latter biopsy is sug-
gested. However, in these systems, the indeterminate category 
can be very broad and include lesions that are likely to be benign 
and thus could safely be followed up without biopsy. By expand-
ing the “indeterminate” category into probably benign, intermedi-
ate probability of HCC, and probably HCC (LI-RADS categories 2, 
3, and 4, respectively), LI-RADS aims for more nuanced and per-
sonalized clinical decision-making.
Prior systems only focus on HCC, rather than address the entire 
spectrum of hepatic lesions. However, it is clinically important to 
differentiate between HCC and other malignancies such as intra-
hepatic cholangiocarcinoma (ICC) or hepatobiliary biphenotypic 
tumor, because the prognosis and management differ consider-
ably. In addition, existing systems neglect the imaging criteria for 
the diagnosis of gross vascular invasion, which has major implica-
tions in staging and treatment.9 In contrast, LI-RADS provides 
separate categories that can be assigned to suspected non-HCC 
malignancies or macrovascular invasive HCC.
LI-RADS is a dynamic system, developed as the product of exist-
ing data and expert radiological and clinical consensus, that will 
continue to be refined and updated as experience and validating 
data accrue and in response to multidisciplinary expert input and 
actively solicited user feedback.10 Since its introduction in 2011, 
LI-RADS has been updated once in 2014. The latest version (cur-
rently ver. 2014) of LI-RADS is available online with extensive sup-
porting information (http://www.acr.org/Quality-Safety/Resourc-
es/ LIRADS). 
This article aims to introduce LI-RADS to clinicians who are not 
radiologists, emphasizing how to use the diagnostic algorithm, in-
terpret LI-RADS categories, and apply LI-RADS to clinical practice. 
THE SCOPE OF APPLICATION
LI-RADS applies only to individuals at high risk for HCC who 
are candidates for or already enrolled in a surveillance program 
for HCC. Thus, LI-RADS should not be applied to those who are 
not at risk for HCC development, and this was to preserve high 
positive predictive value for HCC diagnosis. For example, hepatic 
adenoma or angiomyolipoma can also show the typical enhance-
ment pattern of HCC (arterial hyperenhancement and washout 
appearance), but in most cases these cases are found in individu-
als who are not at high risk for HCC and thus should not be diag-
nosed based on imaging diagnosis criteria. It should be noted 
that LI-RADS does not specifically define this at-risk population, 
nor prescribe the criteria or frequency for HCC surveillance, be-
cause these issues are already addressed by the American Asso-
ciation for the Study of Liver Diseases (AASLD) and other organi-
zations.10
LI-RADS is intended to be used with both liver CT and MRI. 
However, recent studies reported substantial discordance be-
tween CT and MRI in LI-RADS categorization, mainly because of 
the superiority of MRI in detection of the presence of imaging 
features or lesions themselves.11,12 Other studies validating the di-
agnostic performance of LI-RADS published so far have been per-
formed using MRI, which reported high (>95%) positive predic-
tive value and specificity.13,14 Therefore, it is probably safe to 
assume that LI-RADS categorization of focal liver observations is 
dependent on imaging modality, at least until proven otherwise.
There are two main types of contrast media currently used for 
MRI, extracellular and hepatobiliary agents (such as gadoxetic 
acid disodum [Primovist, Bayer Schering Pharma, Berlin, Germa-
ny]); the latter initially distribute in the extracellular fluid compart-
ment, just as extracellular agents do, and are subsequently taken 
up by hepatocytes, providing the dual benefit of dynamic imaging 
capability as well as delayed hepatobiliary phase imaging. Al-
though the 2014 version of LI-RADS has incorporated hepatobili-
ary contrast agents into the diagnostic algorithm, the fact that LI-
RADS has been established from our experiences with 
extracellular agents has not changed, and some features unique 
to hepatobiliary phase imaging are included only as ancillary fea-
tures. More importantly, evaluation of major features is highly 
likely to be affected by the use of hepatobiliary agents, but this 
has not yet been sufficiently investigated.15 For example, early pa-
renchymal enhancement after administration of hepatobiliary 
agents may cause ‘pseudo-washout’ or mask the presence of 
capsule appearance,15-17 but we do not know its exact influences 
on LI-RADS categorization yet. For example, some hepatic hem-
angiomas might show relatively low signal intensity because of 
the uptake of hepatobiliary contrast agent by the surrounding liver 
parenchyma in the delayed phase, not because of true washout, 
thus is called pseudo-washout and can mimic HCC. In addition, 
delayed enhancement of tumor capsule can be masked by concur-
rent enhancement of surrounding liver parenchyma, making it dif-
ficult to recognize the capsule appearance.
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LI-RADS DIAGNOSTIC ALGORITHM
How to use the diagnostic algorithm
The LI-RADS diagnostic algorithm is intended to mimic the nat-
ural thought process of a radiologist who evaluates a hepatic ob-
servation found in patients at risk for HCC. An observation refers 
to an area with imaging features that differ from those of adja-
cent liver parenchyma. The term “observation” is preferred over 
the term “lesion”, because some observations are not true lesions 
but pseudo-lesions such as perfusion alterations or imaging arti-
facts.
The current (v. 2014) LI-RADS has a 5-step hierarchical diagnos-
tic algorithm (Fig. 1). In the first step, you must determine wheth-
er a hepatic observation has previously been treated. If this is the 
case based on history and imaging findings, it is categorized as 
LR-Treated. If not, move on to the second step, in which you must 
determine whether the imaging features are diagnostic of benign 
lesions (LR-1) or suggestive but not diagnostic (LR-2). If so, LR-1 
and LR-2 categories are assigned accordingly. If you think that it is 
neither definitely nor probably benign, move on to the next step. 
In the third step, if you think that even a small possibility of non-
HCC malignancies exists based on the imaging features, LR-M 
category is assigned. If a malignancy other than HCC is thought 
to be unlikely, move on the fourth step, in which you must seek 
the presence of enhancing tumor in vein which indicates the pres-
Figure 1. Summary schematic of LI-RADS 2014 diagnostic algorithm (adapted and modified from ACR LI-RADS content at: http://www.acr.org/Quali-
ty-Safety/Resources/LIRADS). LI-RADS, liver imaging reporting and data system; ACR, American College of Radiology; LR, LI-RADS. *Observations in this 
cell are categorized as LR-4 except as follows: LR-5g, if there is ≥50% diameter increase in ≤6 months, and LR-5us, if there is both “washout” and visibili-
ty as discrete nodules at antecedent surveillance ultrasound.
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ence of macrovascular invasive tumor (LR-5V). If the hepatic ob-
servation does not belong to any of the above-mentioned catego-
ries, you are in the final step. In this step, the observation is 
categorized as LR-3 (indeterminate), LR-4 (probably HCC), or LR-5 
(definitely HCC) according to the likelihood of HCC, based primar-
ily on the presence or absence of major imaging features (de-
scribed below). The final category may be adjusted using ancillary 
features and some specified decision rules (described below).
LI-RADS categories
Brief explanation of each LI-RADS category is presented here 
and also summarized in Table 1. A full description can be found at 
the official website of ACR (http://www.acr.org/Quality-Safety/Re-
sources/ LIRADS). 
LR-1 category is assigned only when there is 100% certainty 
that the observation is benign. Examples of definitely benign enti-
ties that can be categorized as LR-1 include hemangiomas, cysts, 
perfusion alterations, fat deposition or sparing, or focal scars. It 
must be noted that cirrhosis-associated nodules must not be cate-
gorized as LR-1, because non-invasive imaging is unable to reli-
ably exclude the presence of neoplastic changes within nodules.9 
Instead, cirrhosis-associated nodules are either ignored (if they 
are indistinguishable from other background nodules) or, as de-
scribed below, they are categorized as LR-2 or higher. 
LR-2 category is assigned when the imaging features are sug-
gestive, but not diagnostic, of a benign entity. Examples include 
hemangioma with an atypical enhancement pattern and some cir-
rhosis-associated nodules. In order for a cirrhosis-associated nod-
ule to be categorized as LR-2, it should be homogeneous, less 
than 2 cm in diameter, and iso-enhancing relative to background 
liver (Fig. 2). Nodules that do not meet these criteria should be 
categorized as LR-3 or higher depending on their imaging features 
(Fig. 3). 
LR-3 category is assigned to observations that do not meet the 
criteria for other LI-RADS categories and have a moderate proba-
bility of both HCC or a benign entity. Entities that can be catego-
rized as LR-3 include hypovacular nodules larger than 2 cm or 
showing ancillary features such as moderate T2 hyperintensity, or 
subcentimeter arterially enhancing nodules without other imaging 
features favoring HCC (Fig. 3).
LR-4 category is assigned when the imaging features are sug-
gestive, but not diagnostic, of HCC (Fig. 4). If there is a high prob-
ability of HCC but not 100% certainty, the observation must be 
categorized as LR-4, not as LR-5. 
LR-5 category is assigned only when there is 100% certainty 
that the observation is HCC or it is proven to be HCC at histology 
(Fig. 5). For HCC 2 cm or larger, LR-5 observations are equivalent 
to class 5 using the OPTN-UNOS (Organ Procurement and Trans-
plantation Network-United Network for Organ Sharing) system4,18 
Table 1. Definition, examples, and suggested management for each LI-RADS category
LI-RADS 
category
Definition Examples Management
LR-1 Definitely benign Cyst, hemangioma, perfusion alteration, focal 
fat deposit or sparing, observation that 
disappears at follow-up
Continued routine surveillance
LR-2 Probably benign Confluent fibrosis, hypertrophic pseudomass, 
perfusion alteration, some cirrhosis-
associated nodule
Continued routine surveillance
LR-3 Indeterminate Variable follow-up
LR-4 Probably HCC Close follow-up, additional imaging, biopsy, or 
treatment
LR-5 Definitely HCC Treatment without biopsy, radiologic T-staging
LR-5V Definitely tumor invading vein Treatment without biopsy, radiologic T-staging
LR-M Probably malignancy but not 
specific for HCC
Intrahepatic cholangiocarcinoma (CC), 
combined HCC-CC, metastasis, lymphoma, 
post-transplant lymphoproliferative disease
Close follow-up, additional imaging, biopsy, or 
treatment
LR-Treated Treated observation Close follow-up to assess treatment response. 
May require re-treatment if persistent or 
recurrent tumor.
LI-RADS, liver imaging reporting and data system; LR, LI-RADS; HCC, hepatocellular carcinoma.
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and, depending on their size and number, could be used to assign 
priority for liver transplantation in eligible patients.10 As a conse-
quence, some small or early HCCs may be categorized as LR-4 or 
lower. Therefore, clinicians should be aware that an LI-RADS cat-
egory lower than LR-5 does not exclude HCC.
As explained above, one of the goals of LI-RADS is to render 
false-positive diagnoses of HCC as exceedingly rare in patients eli-
gible for liver transplantation. To achieve such high specificity, the 
imaging criteria for LR-5, particularly for 1- to 2-cm observations, 
are more stringent than the AASLD criteria or others. Most 1- to 
2-cm observations with arterial-phase hyperenhancement and a 
single additional major imaging feature are categorized as LR-4. 
However, they can be categorized as LR-5us (‘us’ stands for ‘ultra-
sound’) or LR-5g (‘g’ stands for ‘growth’) depending on the clini-
cal situation (Fig. 4). This practice is to maintain congruency with 
the AASLD’s and the UNOS-OPTN’s diagnostic systems, respec-
tively. LR-5us refers to observations that meet the AASLD diag-
nostic criteria, that is, those that measure 1 to 2 cm, with arterial-
A
C
B
D
Figure 2. An observation that can be categorized as LR-2. At gadoxetic acid-enhanced MRI, a hepatic observation in the segment 5 of liver is distin-
guished from background liver as a 1.7 cm hyperintense nodule on pre-contrast T1-weighted image (arrow) (A), but shows no hyperenhancement in 
the arterial phase (B), no washout appearance in the portal venous phase (C), and iso-intensity on T2-weighted image (D).
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phase hyperenhancement and washout appearance, and were 
visible as discrete nodules at antecedent surveillance US.2 LR-5g 
refers to observations that meet the criteria for OPTN Class 5A-g, 
that is, those that present ≥50% diameter increase in ≤6 
months.4 
LR-5V category is assigned when there is definite enhancing 
soft tissue in a vein irrespective of the presence or absence of visi-
ble intraparenchymal HCC (Fig. 6). This category was created be-
cause macrovascular invasion usually constitutes a contraindica-
tion to curative treatments such as liver transplantation and 
hepatic resection.
LR-M category is assigned to observations that are probably 
malignant but not specific for HCC, such as those with imaging 
features suggestive of ICC, biphenotypic tumor, lymphoma, me-
tastasis, or post-transplant lymphoproliferative disorder (Fig. 7). 
LR-Treated category is assigned to treated observations, and is 
currently under development. Criteria for assessment of residual 
or recurrent disease based on the type of therapy will be released 
in future versions of LI-RADS.7
Major imaging features
Major features are imaging features used to categorize LR-3, 
LR-4, and LR-5 observations, and include arterial-phase hyperen-
A
C
B
D
Figure 3. An observation that can be categorized as LR-3. At gadoxetic acid-enhanced MRI, a 1.2 cm nodule in the hepatic dome shows no arterial 
hyperenhancement (A). However, this observation would be better categorized as LR-3 than as LR-2, because of the presence of washout appearance 
in the portal venous phase (B) and some ancillary features such as hepatobiliary phase hypointensity (C) and moderate T2 hyperintensity (D).
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hancement, tumor diameter, washout appearance, capsule ap-
pearance, and threshold growth. Major features should be consid-
ered present only if their presence is unequivocal, in order to 
maintain high specificity for HCC.
Tumor diameter is defined as the largest dimension of an obser-
vation, measured from outer edge to outer edge in the imaging 
sequence, phase, and plane in which the margins are most sharply 
demarcated. In LI-RADS, observations are classified into two or 
three categories according to the size criteria (<2 cm vs. ≥2 cm 
for hypovascular observations, and <1 cm vs. 1-2 cm vs. ≥2 cm 
for hypervascular observations), because larger observations are 
associated with a higher likelihood of HCC and progression.19,20 In 
LI-RADS, observations <1 cm cannot be categorized as definitely 
HCC (LR-5). 
Arterial phase hyperenhancement is defined as contrast-en-
hancement in the arterial phase that is unequivocally greater than 
that of the surrounding liver parenchyma (Figs. 4 and 5). This is 
thought to reflect the gradual change in blood supply from portal 
to arterial due to capillarization and neoarterialization that ac-
companies the development of progressed HCC.21 Arterial phase 
hyperenhancement is an essential prerequisite for definitely HCC 
(LR-5). However, it is non-specific and may be observed in benign 
entities such as hemangiomas, focal nodular hyperplasia, high-
grade dysplastic nodules, and arterioportal shunts. Therefore, ar-
terial phase hyperenhancement is required but not sufficient for 
LR-5 categorization; it must be observed in combination with oth-
A B
C D
Figure 4. An observation that can be categorized as LR-4, LR-5us, or LR-5g depending on the clinical situation. In the arterial phase of gadoxetic acid-
enhanced MRI (arrow) (A), this 1.2 cm subcapsular lesion in the segment 7 of liver shows hyperenhancement, which is more definite in the subtraction 
image (arrow) (B), which is more definite in the subtraction image (B). In the portal venous (C) and delayed (D) phases, the lesion shows washout ap-
pearance but no capsule appearance. Because the nodule is smaller than 2 cm, this lesion cannot be categorized as LR-5 despite the presence of the 
radiologic hallmark of hepatocellular carcinoma (arterial hyperenhancement and washout). However, this 1- to 2-cm nodule with the radiologic hall-
mark can be categorized as LR-5, if it was previously detected at US (LR-5us) or showed ≥50% diameter increase in ≤6 months (LR-5g). 
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er major features discussed below. 
Washout appearance is defined as temporal reduction in con-
trast-enhancement relative to liver from an earlier to a later phase 
resulting in hypoenhancement in portal venous or delayed phase 
(Fig. 5). This may reflect multiple concomitant phenomena: rapid 
venous drainage, reduced portal venous supply to progressed 
HCC22 and later enhancement of the background liver especially 
with hepatobiliary agents used as MRI contrast media.16 Like arte-
rial phase hyperenhancement, washout appearance by itself is not 
specific for HCC, as this feature may be observed in cirrhosis-as-
sociated nodules or pseudolesions such as focal areas of paren-
chymal distortion and enhancing fibrosis.9 
Capsule appearance is defined as a peripheral rim of smooth 
hyperenhancement in the portal venous or delayed phase that is 
unequivocally thicker or more conspicuous than the rims sur-
rounding background nodules (Fig. 5). The rim of enhancement 
does not always represent a true tumor capsule, but may instead 
represent a pseudocapsule corresponding to loose fibrous tissue 
and dilated sinusoids around a nodule.23 The capsule appearance 
may permit the diagnosis of HCC in the absence of definite wash-
out appearance, although it is usually seen in combination with 
other major imaging features.24,25
Threshold growth is defined as an increase in the diameter of 
an observation by both a minimum of 5 mm and a sufficient rate. 
The required growth rate is either at least a 50% increase in di-
ameter compared with baseline within 6 months or at least a 
100% increase in diameter over more than 6 months.
LI-RADS Table
The decision to assign LR-3, LR-4, or LR-5 categories to obser-
vations is based on the selection of appropriate columns and rows 
A B
C D
Figure 5. An observation that can be categorized as LR-5. In the pre-contrast T1-weighted image (A) and arterial (B), portal venous (C), and delayed (D) 
phases of gadoxetic acid-enhanced MRI, this 1.3 cm nodule unequivocally shows arterial hyperenhancement (B), washout appearance (C), and capsule 
appearance (C and D).
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A B
Figure 7. An observation that can be categorized as LR-M. At gadopentetate-enhanced MRI, a 4-cm mass in the segment 5 of liver shows irregular 
peripheral enhancement and peritumoral parenchymal enhancement in the arterial phase (A) and peripheral washout and central enhancement in 
the delayed phase (B). These imaging features favor other malignancy over hepatocellular carcinoma (HCC).
A B
C D
Figure 6. An observation that can be categorized as LR-5V. In the pre-contrast (A), arterial (B), portal venous (C), and delayed (D) phases of dynamic 
liver CT, ill-defined infiltrative lesions are diffusely involving the right posterior hepatic section (arrow), with expansile tumor thrombi in both main por-
tal vein branches (arrowheads).
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in the LI-RADS table embedded in Figure 1. The column is select-
ed according to the enhancement pattern (arterial phase hypo- or 
iso-enhancement vs. hyperenhancement) and diameter. The row 
is selected according to the number of major features present 
among the following: washout appearance, capsule appearance, 
and threshold growth. The appropriate category is found at the 
intersection of column and row selected. As stated earlier, 1-2 cm 
observations with arterial-phase hyperenhancement and a single 
additional major feature are categorized as either LR-4, LR-5us (if 
it was visible at antecedent US), or LR-5g (if diameter increased 
by ≥50% in ≤6 months).
Ancillary imaging features
Ancillary features are imaging features that can be used to ad-
just the LI-RADS category at users’ discretion (Fig. 3). In isolation, 
these features do not permit reliable categorization of observa-
tions. There is not yet sufficient scientific evidence to mandate 
their use. Ancillary features favoring malignancy (including diffu-
sion restriction, mosaic architecture, and moderate T2 hyperinten-
sity) can be used to upgrade category by one or more categories, 
but not beyond LR-4 in order to maintain high specificity for HCC 
and congruency with the UNOS-OPTN and other guidelines. In 
contrast, ancillary features favoring benignity (including homoge-
nous marked T2 hyperintensity or hypointensity, and diameter re-
duction or stability) can be used to decrease category down to 
LR-1 as appropriate.
A complete description of the major and ancillary imaging fea-
tures is beyond the scope of this article, but detailed descriptions 
and supporting illustrations are available online (http://www.acr.
org/Quality-Safety/Resources/ LIRADS). 
Tie-breaking rules
Tie-breaking rules can be used to adjust the category, if, after 
application of the algorithm and ancillary features, a user is still 
unsure about the final category for an observation (Fig. 8). These 
rules move observations to a category with a lower degree of cer-
tainty. For example, if unsure whether an observation should be 
categorized as LR-4 or LR-3, the rules would recommend the ob-
servation be categorized as LR-3. If there is concern that an LR-4 
or LR-5 observation may represent a non-HCC malignancy, then it 
should be categorized as LR-M so as to avoid inappropriate man-
agement.
MANAGEMENT IMPLICATIONS
For observations without a definite diagnosis by imaging (LR-2, 
LR-3, and LR-4), a clinician’s estimated probability of HCC should 
not depend solely on the LI-RADS category, but also on factors 
such as tumor markers and the patient’s previous probability of 
developing or having HCC.10 Furthermore, the decision regarding 
the next step in a patient’s management should also depend on 
Figure 8. Tie breaking rules to adjust 
category. If still unsure about the final 
category for an observation after appli-
cation of ancillary features, these tie-
breaking rules should be applied. LR, LI-
RADS.
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factors other than the likelihood of HCC, such as comorbidities, 
patient preference, or technical difficulty of biopsy. Thus, deci-
sions between accelerated follow-up, alternative imaging, biopsy, 
or treatment without biopsy do not follow directly from the LI-
RADS category or from a clinician’s estimated probability of HCC, 
but rather from a clinical assessment that integrates all available 
medical information. However, the LI-RADS category may facili-
tate management decisions by clearly communicating the contri-
bution of imaging toward determining the likelihood of HCC. It 
should be noted that LI-RADS does not address management of 
nodules with a definite diagnosis of HCC (LR-5), because this is 
covered by the other guidelines. 
CONCLUSIONS
LI-RADS is a comprehensive system for interpreting and report-
ing the full spectrum of hepatic observations in patients at high 
risk for HCC. One of the most important goals is to facilitate clear 
communication between all the personnel involved in the diagno-
sis and treatment of HCC, such as radiologists, hepatologists, sur-
geons, and pathologists. Therefore, in order to achieve this goal, 
clinicians should also be familiar with the LI-RADS diagnostic al-
gorithm, and with the definitions and management implications 
of LI-RADS categories. 
LI-RADS, like the other imaging-based diagnostic systems, does 
have limitations and problems to be addressed. However, LI-RADS 
is being constantly refined and updated in response to advances 
in our knowledge and technology. Therefore, LI- RADS will con-
tinue to evolve as a comprehensive and up-to-date system that 
will provide standardized imaging assessment of liver diseases for 
clinical care and research.
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